Prostate Drug Price Controls Come at Too High a Cost

Health and Human Services Secretary Xavier Becerra is facing mounting pressure to unilaterally lower the price of high-cost medications.

A group of nonprofits just petitioned him to cut the cost of six medications, including Xtandi, a popular prostate cancer medicine manufactured by Astellas, a Japanese drug company. The move follows a similar petition, amplified by roughly a dozen members of the House and Senate, that's focused solely on Xtandi.